2025 annual financial data
Hemab Therapeutics 2025 Operating margin
Hemab Therapeutics 2025 operating margin with verified reported values.
Direct answer
Operating margin was Not calculable.
Operating income was -70,119,000 USD and net income was -63,913,000 USD.
Operating cash flow was -61,475,000 USD.
Get free Hemab Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 0 USD
- Operating income
- -70,119,000 USD
- Net income
- -63,913,000 USD
- Operating cash flow
- -61,475,000 USD